Day: May 13, 2023

Posted on

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Telephone and Data Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TDS, TDSPrU, TDSPrV

NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telephone and Data Systems, Inc. (the “Company” or “TDS”) (NYSE: TDS, TDSPrU, TDSPrV) between May 6, 2022 and November 3, 2022, both dates inclusive (the “Class Period”), of the important July 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased TDS securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TDS class action, go to https://rosenlegal.com/submit-form/?case_id=15807 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the Company and its subsidiary, United States Cellular Corporation (“UScellular”), made false and/or misleading statements and/or failed to disclose that: (1) defendants had no reason to believe UScellular’s “free upgrade” promotional activity, which was tested and trialed during the second quarter of 2022, was effective at reducing the Company’s postpaid churn rate as they represented to investors, as opposed to merely adding new postpaid subscribers, when its churn rate was actually increasing or remaining constant over most quarters in the class period; (2) UScellular was not making progress with respect to its churn rate, as it represented to investors; (3) UScellular was not in fact balancing its promotional activity and its profitability; (4) due to extreme competition among postpaid carriers, UScellular did not have the flexibility to offset the costs from widespread, expensive promotions with price increases; and (5) as a result of the Companies’ decision for UScellular to continue engaging in heavy promotions to address its postpaid subscriber churn rate despite any lack of positive impact on churn rate, UScellular’s profitability substantially declined. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TDS class action, go to https://rosenlegal.com/submit-form/?case_id=15807 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

GlobeNewswire Distribution ID 8838498

Posted on

Insilico Medicine Founder and CEO to Give Keynote on Disease Modeling with AI at PEGS Boston

Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)-driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the PEGS Boston Summit from May 15-19. He will deliver a keynote presentation on “The State of the Science in Disease Modeling Across Diverse Indications” on May 15 at 11AM at the Hynes Convention Center and join in an interactive discussion on May 15 at 12:45PM.

In his presentation, Dr. Zhavoronkov will make the first announcement of peptide-based drug design strategies and Generative Biologics, a new engine that belongs to the company’s end-to-end AI-driven drug discovery platform Pharma.AI that leverages hundreds of millions of biological data points, machine learning algorithms, and generative biology models to build and design polypeptides from scratch.

A team of expert scientists are developing Pharma.AI at the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Center in Abu Dhabi, the region’s largest AI-powered biotechnology research center.

“We are at an exciting moment in the history of generative AI in drug discovery,” says Zhavoronkov. “Thanks to years of accumulated data and technological advances in generative AI, we can find targets and design new small molecules for hard-to-treat diseases with incredible speed and efficiency working in close partnership with pharmaceutical companies. We look forward to using generative AI to explore diverse drug development strategies.”

Insilico Medicine was one of the first companies to use generative adversarial autoencoders for de-novo drug discovery. In 2016, the Company introduced the earliest iternation of its generative biology tool for identifying novel targets with a publication in Nature Communications. Another publication followed in Oncotarget, demonstrating how Insilico could employ generative algorithms with reinforcement learning to design novel small molecules with predefined and optimized properties. By 2018, Insilico integrated generative biology and chemistry approaches into the commercially available Pharma.AI platform that accelerates the process of lead discovery from years to days, and is currently being utilized by 11 of 20 top pharmaceutical companies.

The Company has also utilized the platform to develop its own robust pipeline of assets, including two drugs – for idiopathic pulmonary fibrosis and COVID-19 – currently in clinical trials and many potentially best-in-class and first-in-class assets in preclinical stages of development available for licensing. In total, Insilico has 31 programs across 29 targets, including in fibrosis, oncology, immunology, and central nervous system disorders.

Zhavoronkov says PEGS, the world’s largest gathering of protein engineering and biotherapeutics experts, is the perfect setting for announcing the latest developments to Insilico’s platform. “We were instrumental in the early development of generative biology and generative chemistry, and now we’re advancing AI-designed drugs into clinical trials. It is truly a pivotal moment.”

About Insilico Medicine

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. In early 2023, the Company opened the Insilico Medicine Generative Artificial Intelligence and Quantum Computing Research and Development Centre in Abu Dhabi, the region’s largest AI-powered biotechnology research center. The R&D hub brings together global talent in artificial intelligence and software development to expand the capabilities of Insilico’s end-to-end AI-driven drug discovery platform, Pharma.AI, explore aging research and sustainable chemistry, and support the digital transformation of healthcare in the region.

For more information, visit www.insilico.com

Attachment

Brita Belli
Insilico Medicine
475-225-0843
brita@insilico.com

GlobeNewswire Distribution ID 8838633

Posted on

Saudi Foreign Minister Receives Telephone Call from Iranian Foreign Minister

Prince Faisal bin Farhan bin Abdullah, Minister of Foreign Affairs, received today a phone call from Minister of Foreign Affairs of the Islamic Republic of Iran, Hossein Amir Abdollahian.

During the telephone conversation, the two sides reviewed bilateral relations and ways of developing them in various fields, in addition to discussing many issues of interest to both countries and the next steps in light of recent agreements with the People’s Republic of China.

Source: Saudi Press Agency

Posted on

IsDB, AHTF Sign Partnership Agreements to Improve Infrastructure, Support Families in Afghanistan

The Islamic Development Bank (IsDB) signed four agreements with the Afghanistan Humanitarian Trust Fund (AHTF) under which a number of infrastructure projects will be implemented in Afghanistan.

The agreements were signed in the presence of the Chairman of the Board of Directors of IsDB Group, Dr. Mohammed Al-Jasser, on the sidelines of the bank’s annual meetings in Jeddah.

As a trustee of the AHTF, the IsDB signed a partnership agreement with the Danish Committee for Aid to Afghan Refugees (DACAAR) for a project to facilitate access to clean water in underprivileged regions in Afghanistan.

Under the agreement, the AHTF will extend a grant of $540,000 to DACAAR to secure sustainable access to clean water for Afghan refugees and vulnerable communities in Kabul, Nangarhar, Kunduz, and Faryab provinces. A total of 13,300 people will benefit from the project under which solar-powered pumping systems and water pipes will be established.

The second agreement was signed between the IsDB, as a trustee of the AHTF, and the International Medical Corps UK, which aims to implement a sewage and environment protection project in the communities affected by conflicts and natural disasters in Paktika Province.

Under the agreement, the AHTF will extend a grant of $1,078,849 to the International Medical Corps as a contribution from the King Salman Humanitarian Aid and Relief Center.

The third agreement was signed between the IsDB, as an executive partner, and the International Organization for Migration (IOM) to build a total of 29 family healthcare centres in Afghanistan’s rural regions.

The fourth agreement was signed between the IsDB, also in its capacity as an executive partner, and the Aga Khan Foundation, which aims at supporting sustainable and comprehensive transformation into agricultural economies in rural areas.

Source: Saudi Press Agency

Posted on

Conference of French-Speaking Business Owners to kick off next Monday

Under Royal patronage, activities of the 4th Conference for French-Speaking Business Owners is scheduled to begin next Monday in the Dead Sea region, under the theme: “Jordan: The Land of Promising Opportunities for International Investors.” Organized by Jordan Businessmen Association (JBA), in cooperation with a group of French-speaking businesspeople, the conference will see participation of 200 investors and economic experts in various fields, as well as several local, Arab and international companies and institutions. JBA President and head of the conference’s preparatory committee, Hamdi Tabba’a, said the event is held for the first time in a non-French-speaking country, with participation of 16 countries, including Jordan, and features 12 sessions during which 60 personalities speak. In a statement on Saturday, he said the two-day event constitutes an “important” opportunity to enhance trade and investment cooperation between French-speaking companies and institutions and Middle East and North Africa countries. The conference, he noted, provides participants with an opportunity to expand their business relations and contact business owners. Tabba’a added that the conference will contribute to facilitate access to French-speaking markets, and providing “new” horizons for building trade and investment ties and partnerships and further networking participants, through joint meetings and exchange of expertise in various fields. The event also constitutes an opportunity for investors to assess Jordan’s investment opportunities and learn about potential investment in various economic sectors and a platform for exchanging expertise in diverse fields, primarily technology, artificial intelligence, renewable energy and other industries to support stimulating innovation and developing industries, he said. According to Tabba’a, the conference aims to empower women and develop startups projects, in addition to strengthening role of the French language as an “important” means in doing business, and mechanisms to enhance trade and investment relations with Francophone-African countries. He stressed the JBA’s keenness to promote the Kingdom’s investment and business environment, by harnessing its deep-rooted relations with the Arab and foreign private sector, and joint partnership councils that link it with multiple local and international institutions. In addition to Jordan, France, Belgium, Tunisia, Algeria, Canada, Romania, Ivory Coast, Egypt, UAE, Croatia, Nigeria, Cameroon, Benin, Palestine and Senegal are scheduled to participate in the conference.

Source: Jordan News Agency

Posted on

Labor ministry received 13,996 grievances during 2022-Report

Ministry of Labor received a total of 13,996 labor complaints during 2022 on Hemaya (Protection) platform to file labor grievances, of which 13,580 were settled with employers and workers’ rights were restored. According to a report obtained by “Petra,” 69 complaints were not transferred to concerned authorities and 347 others are under procedure, as well as 87 child labor complaints, of which the ministry resolved 85 with employers and the 2 remaining cases are currently being addressed. The highest number of complaints pertained to wage non-payment, which stood at 5,508, while grievances related to termination of service for an indefinite-term work contract, or absence of an employment contract amounted to 1,544, the report indicated. In addition, work suspension complaints hit 1,108, while 480 others pertained to failure to issue an experience certificate and 375 related to failure to pay minimum wage, the report showed. The report also indicated that a total of 22,896 visits were carried out by the authorities’ inspection teams during 2022, as 4,714 violations were recorded and 1,703 facilities were alerted. Child labor cases detected during the visits amounted to 520, as 142 facilities were warned and 160 establishments were issued violation tickets, the report revealed.

Source: Jordan News Agency